Oxford Biomedica announces
Chief Financial Officer transition
- Lucinda Crabtree
to join as Chief Financial Officer -
Oxford, UK - 17 July 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or
"the Company"), a quality and innovation-led cell and gene therapy
CDMO, today announces the appointment of Lucinda (Lucy) Crabtree
Ph.D. as Chief Financial Officer (CFO) and Board member.
Simultaneously, the Company announces that Stuart Paynter will step
down as CFO and from the Board after almost seven years of service.
These changes will become effective on 2 September 2024 and Stuart
will then transition away from Oxford Biomedica following a
suitable handover period.
Lucinda Crabtree was previously CFO
at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team
across the US and Germany until the closing of the acquisition of
the company by Novartis. Prior to MorphoSys, Lucy was CFO at
Autolus Therapeutics, a Nasdaq listed clinical stage
biopharmaceutical company. Before her time at Autolus, Lucy spent
several years as an investment professional at institutions
including Woodford Investment Management, Panmure Gordon, Goldman
Sachs, J.P. Morgan (originally Bear Stearns) and Jefferies. Lucy
also has prior experience as a board observer at several private
healthcare companies. She holds a first class Bachelor of Science
degree in Physiology and Pharmacology from University College
London and a Ph.D. in Pharmacology from University College
London.
Dr.
Frank Mathias, Chief Executive Officer of Oxford Biomedica,
commented: "On behalf of the corporate
executive team, I am delighted to welcome Lucy to Oxford Biomedica.
Her unique skillset will be immensely valuable to us as we enter
the next phase of our growth as a pure-play CDMO. I would also like
to warmly thank Stuart for his dedicated service to OXB. Since
joining the Company nearly seven years ago, Stuart has been
instrumental in its success right the way through to the recent
transformation of our business model. We wish him all the best for
his future endeavours."
Stuart Paynter said:
"It has
been a pleasure and a privilege to help lead Oxford Biomedica
through its development to its position as a leading CDMO. The
Company is now operationally and financially in stronger health
than ever before and, with the transformation complete, it is now
the natural time to hand over to someone with Lucy's skills and
experience. I look forward to continuing to support OXB in the
interim and then as it enjoys further success and momentum in the
future."
Lucinda Crabtree said:
"This is
an exciting time to join Oxford Biomedica, having entered a new
phase as an international pure-play cell and gene therapy CDMO. I
look forward to working with Frank and the senior leadership team
alongside the Board, as we continue to execute on this integrated
strategy and continue our growth in the backdrop of a rapidly
expanding cell and gene therapy market."
Relevant disclosures
There are no disclosures required to
be made in accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica
plc:
Sophia Bolhassan, VP, Corporate Affairs and IR - T:
+44 (0) 1865 509 737 / E: ir@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 / E:
oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Angela Gray / Davide
Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a
quality and innovation-led contract development and manufacturing
organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients
around the world.
One of the original
pioneers in cell and gene therapy, OXB has more than 25 years of
experience in viral vectors; the driving force behind the majority
of cell and gene therapies. OXB collaborates with some of the
world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and
manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods
and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good
constituent, is headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across
Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA,
US. Learn more at www.oxb.com, and follow us
on LinkedIn and YouTube.